Holen Sie sich die Stockscreener-App
1.19
1.24%
-0.015
Handel nachbörslich:
1.18
-0.01
-0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.205
Offen:
$1.2
24-Stunden-Volumen:
6.65M
Relative Volume:
2.15
Marktkapitalisierung:
$430.18M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.75
EPS:
-0.68
Netto-Cashflow:
$-162.37M
1W Leistung:
-41.38%
1M Leistung:
-29.59%
6M Leistung:
-31.61%
1J Leistung:
-19.59%
1-Tages-Spanne:
$1.01
$1.20
1-Wochen-Bereich:
$1.01
$2.08
52-Wochen-Spanne:
$0.92
$3.73
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - Barchart
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
Needham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon’s Sotagliflozin Returns To US FDA Panel With Narrowed Indication - Citeline
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 9.7%Here's Why - MarketBeat
Lexicon looks to go where no other oral drug has gone before - BioWorld Online
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More - MSN
Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN
Lexicon reports renal benefits of diabetes drug in trial By Investing.com - Investing.com Australia
Institutions profited after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap rose US$54m last week but private equity firms profited the most - Simply Wall St
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) - Benzinga
Lexicon reports renal benefits of diabetes drug in trial - Investing.com India
Lexicon Pharma (LXRX): New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN - StreetInsider.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by HC Wainwright - MarketBeat
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.5% HigherTime to Buy? - MarketBeat
Lexicon pens licensing deal with Viatris for sotagliflozin - The Pharma Letter
Lexicon signs global sotagliflozin license with Viatris By Investing.com - Investing.com Australia
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights - Benzinga
Viatris Enters Exclusive Licensing Agreement With Lexicon - Contract Pharma
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon partners Viatris for global expansion of sotagliflozin - Yahoo Finance
Viatris to market Lexicon Pharma’s sotagliflozin outside US and Europe - World Pharmaceutical Frontiers
Viatris to market Lexicon's sotagliflozin outside of US, Europe (NASDAQ:VTRS) - Seeking Alpha
Lexicon Pharmaceuticals inks deal with Viatris for sotagliflozin - Investing.com
Lexicon Pharmaceuticals inks deal with Viatris for sotagliflozin By Investing.com - Investing.com UK
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - The Manila Times
Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Exclusive Licensing Agreement with Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - Marketscreener.com
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - StockTitan
Financial Metrics Check: Lexicon Pharmaceuticals Inc (LXRX)’s Ratios for Trailing Twelve Months - The Dwinnex
Have you been able to find a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes (LXRX) - Seeking Alpha
Lexicon signs global sotagliflozin license with Viatris - Investing.com
A Look at Lexicon Pharmaceuticals Inc (LXRX) Shares in the Recent Past Indicates Growth - SETE News
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):